489 related articles for article (PubMed ID: 23835718)
21. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
22. Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.
Dawson K; Moran M; Guindon K; Wan H
Clin J Oncol Nurs; 2016 Apr; 20(2):E41-8. PubMed ID: 26991722
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
[TBL] [Abstract][Full Text] [Related]
25. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
Cartron G; de Guibert S; Dilhuydy MS; Morschhauser F; Leblond V; Dupuis J; Mahe B; Bouabdallah R; Lei G; Wenger M; Wassner-Fritsch E; Hallek M
Blood; 2014 Oct; 124(14):2196-202. PubMed ID: 25143487
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
[TBL] [Abstract][Full Text] [Related]
27. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S; Beldi-Ferchiou A; Alcantara M; Cacheux V; Safar V; Burroni B; Guidez S; Gastinne T; Canioni D; Thieblemont C; Maisonneuve H; Bodet-Milin C; Houot R; Oberic L; Bouabdallah K; Bescond C; Damaj G; Jaccard A; Daguindau N; Moreau A; Tilly H; Ribrag V; Delfau-Larue MH; Hermine O; Macintyre E
Lancet Haematol; 2020 Nov; 7(11):e798-e807. PubMed ID: 32971036
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP; Forero-Torres A; Costa LJ; Flinn IW; Inhorn L; Kelly K; Bessudo A; Fayad LE; Kaminski MS; Evens AM; Flowers CR; Sahin D; Mundt KE; Sandmann T; Fingerle-Rowson G; Vignal C; Mobasher M; Zelenetz AD
Leuk Lymphoma; 2019 Apr; 60(4):894-903. PubMed ID: 30277102
[TBL] [Abstract][Full Text] [Related]
29. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
30. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Radford J; Davies A; Cartron G; Morschhauser F; Salles G; Marcus R; Wenger M; Lei G; Wassner-Fritsch E; Vitolo U
Blood; 2013 Aug; 122(7):1137-43. PubMed ID: 23843495
[TBL] [Abstract][Full Text] [Related]
33. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
34. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
35. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
37. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
38. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
Shah A
Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
40. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
